Erasca remains a pre-revenue clinical-stage biotech with no product sales across ten reported quarters, and its trajectory hinges entirely on pipeline milestones.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.14-25.7% vs -$0.11 | — vs — |
Q2 2026 May 11, 2026 | -$0.60-438.0% vs -$0.11 | — vs — |
Q2 2026 Mar 12, 2026 | -$0.10+9.1% vs -$0.11 | — vs — |
Q4 2025 Nov 12, 2025 | -$0.11+0.0% vs -$0.11 | — vs — |
Shares of Erasca, Inc. (NASDAQ: ERAS - Get Free Report) fell 5.8% on Friday. The stock traded as low as $13.86 and last traded at $14.0050. Approximately 228,699 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 5,876,580 shares. The stock had previously closed at $14.87. Analyst Upgrades and
PHILADELPHIA, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ: AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company's February 13, 2025, initial public offering (IPO) and have continued to hold their shares.
Erasca (ERAS) is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential registration-enabling trials ahead. Daraxonrasib's FDA approval validates the RAS mechanism, shifting competition to tolerability and dose intensity, where ERAS-0015 shows potential differentiation. ERAS-0015 demonstrates strong tolerability, no dose-limiting toxicities, and high dose intensity, supporting its case for durable efficacy in key indications.
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The
Benchmark ERAS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Erasca, Inc. (ERAS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.41 | $5B | -15.62 | — | — | -80.43% | — | |
| $192.28 | $40.88B | -22.10 | — | -946.82% | -91.93% | — | |
| $21.50 | $3.5B | -26.04 | 48.29% | -229.92% | -25.74% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $2.33 | $148.1M | -10.15 | 0.78% | -8.7% | -31.27% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — |
Erasca, Inc. (ERAS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Erasca, Inc. (ERAS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Aug 10, 2026·SEC
Jul 14, 2026·SEC
Get notified when ERAS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Erasca, Inc. (ERAS) stock FAQ — growth, dividends, profitability & financials explained
No. Erasca, Inc. (ERAS) reported a net loss of $287.2M over the trailing twelve months.
Erasca, Inc. (ERAS) had a return on equity (ROE) of -80.4% over the trailing twelve months. A negative ROE means the company lost money over the period.
Erasca, Inc. (ERAS) had negative free cash flow of $98.1M over the trailing twelve months.
